BRPI0412879A8 - Conjugado citotóxico específico do antígeno ca6 e métodos de seu uso - Google Patents
Conjugado citotóxico específico do antígeno ca6 e métodos de seu usoInfo
- Publication number
- BRPI0412879A8 BRPI0412879A8 BRPI0412879A BRPI0412879A BRPI0412879A8 BR PI0412879 A8 BRPI0412879 A8 BR PI0412879A8 BR PI0412879 A BRPI0412879 A BR PI0412879A BR PI0412879 A BRPI0412879 A BR PI0412879A BR PI0412879 A8 BRPI0412879 A8 BR PI0412879A8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- antigen specific
- specific cytotoxic
- cytotoxic
- conjugate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
Abstract
ANTICORPO OU SEU FRAGMENTO DE LIGAÇÃO AO EPÍTOPO, POLINUCLEOTÍDEO, VETOR, CONJUGADO CITOTÓXICO ESPECÍFICO DO ANTÍGENO CA6, MÉTODO DE SEU USO, COMPOSIÇÃO TERAPÊUTICA E KIT. A presente invenção refere-se a conjugados citotóxicos compreendendo um agente de ligação celular e um agente citotóxico, composições terapêuticas compreendendo o conjugado, métodos para uso dos conjugados na inibição do crescimento celular e o tratamento de doença, e um kit que compreende o conjugado citotóxico, sendo todos formas de realização da invenção. Em particular, o agente de ligação celular é um anticorpo monocional e seus fragmentos de ligação ao epitopo, que reconhece e se liga ao glicótopo CA6. A presente invenção é também direcionada às versões humanizadas ou reemergidas de DS6, um anticorpo anti-CA6 monoclonal de murino e seus fragmentos de ligação ao epitopo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48844703P | 2003-07-21 | 2003-07-21 | |
PCT/US2004/023340 WO2005009369A2 (en) | 2003-07-21 | 2004-07-21 | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0412879A BRPI0412879A (pt) | 2006-10-03 |
BRPI0412879A8 true BRPI0412879A8 (pt) | 2015-12-15 |
Family
ID=34102763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412879A BRPI0412879A8 (pt) | 2003-07-21 | 2004-07-21 | Conjugado citotóxico específico do antígeno ca6 e métodos de seu uso |
Country Status (27)
Country | Link |
---|---|
US (1) | US20050123549A1 (pt) |
EP (1) | EP1660513B9 (pt) |
JP (5) | JP2007503202A (pt) |
KR (5) | KR101263950B1 (pt) |
CN (3) | CN103145844B (pt) |
AT (1) | ATE496944T1 (pt) |
AU (1) | AU2004258955C1 (pt) |
BR (1) | BRPI0412879A8 (pt) |
CA (1) | CA2532430C (pt) |
CR (1) | CR8207A (pt) |
CY (1) | CY1111938T1 (pt) |
DE (1) | DE602004031239D1 (pt) |
DK (1) | DK1660513T5 (pt) |
EA (1) | EA014640B1 (pt) |
EC (1) | ECSP066294A (pt) |
ES (1) | ES2360403T3 (pt) |
HK (2) | HK1098160A1 (pt) |
HR (1) | HRP20110302T1 (pt) |
IL (2) | IL172982A (pt) |
MX (2) | MXPA06000830A (pt) |
NO (1) | NO339324B1 (pt) |
NZ (3) | NZ612796A (pt) |
PL (1) | PL1660513T3 (pt) |
PT (1) | PT1660513E (pt) |
SI (1) | SI1660513T1 (pt) |
WO (1) | WO2005009369A2 (pt) |
ZA (1) | ZA200600375B (pt) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US9539348B2 (en) | 2000-08-18 | 2017-01-10 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
PT1651162E (pt) * | 2003-05-20 | 2016-02-22 | Immunogen Inc | Agentes citotóxicos melhorados compreendendo novos maitansinóides |
US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
WO2007024222A1 (en) * | 2005-08-22 | 2007-03-01 | Immunogen, Inc. | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
CN104804094A (zh) * | 2005-08-22 | 2015-07-29 | 伊缪诺金公司 | Ca6抗原特异性细胞毒性偶联物及其应用方法 |
SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
PT2242772E (pt) * | 2007-12-26 | 2015-02-09 | Biotest Ag | Imunoconjugados dirigidos contra cd138 e as suas utilizações |
EP2238169A1 (en) * | 2007-12-26 | 2010-10-13 | Biotest AG | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
EP2238168B8 (en) * | 2007-12-26 | 2014-07-23 | Biotest AG | Agents targeting cd138 and uses thereof |
BRPI0821417A2 (pt) * | 2007-12-26 | 2015-06-16 | Biotest Ag | Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo |
SG189811A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
NZ596807A (en) * | 2009-05-06 | 2013-09-27 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
JP6162606B2 (ja) * | 2011-01-14 | 2017-07-12 | レッドウッド バイオサイエンス, インコーポレイテッド | アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 |
JP6088488B2 (ja) | 2011-04-21 | 2017-03-01 | シアトル ジェネティックス, インコーポレイテッド | 新規な結合剤−薬物複合体(adc)およびそれらの使用 |
EP2758430A4 (en) * | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
US10117932B2 (en) | 2011-12-08 | 2018-11-06 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
JP2012161321A (ja) * | 2012-03-30 | 2012-08-30 | Immunogen Inc | Ca6抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法 |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
WO2014122529A1 (en) | 2013-02-05 | 2014-08-14 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US9844607B2 (en) | 2013-02-05 | 2017-12-19 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
CN111537426A (zh) | 2013-03-15 | 2020-08-14 | 贝克曼考尔特公司 | 用于设计流式细胞术中的面板的***和方法 |
US20160347856A1 (en) * | 2013-08-02 | 2016-12-01 | Sanofi | Use of Anti-MUC1 Maytansinoid Immunoconjugate Antibody for the Treatment of Solid Tumors |
RU2698697C2 (ru) | 2013-12-23 | 2019-08-29 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего (ADC) с ингибиторами KSP |
JP2017509337A (ja) * | 2014-03-12 | 2017-04-06 | ノバルティス アーゲー | イムノコンジュゲートを作製する抗体を修飾するための特定部位 |
EP3188761A4 (en) | 2014-09-02 | 2018-04-18 | ImmunoGen, Inc. | Methods for formulating antibody drug conjugate compositions |
CN116514903A (zh) | 2014-09-03 | 2023-08-01 | 伊缪诺金公司 | 细胞毒性苯并二氮杂䓬衍生物 |
US9381256B2 (en) | 2014-09-03 | 2016-07-05 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
MX2017017172A (es) | 2015-06-22 | 2018-02-23 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
US20170189548A1 (en) | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
KR102556826B1 (ko) | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
JP7174704B2 (ja) | 2016-12-21 | 2022-11-17 | バイエル・アクチエンゲゼルシヤフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
RU2765098C2 (ru) | 2017-02-28 | 2022-01-25 | Иммуноджен, Инк. | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты |
US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
EP3732178A1 (en) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
AU2020242284A1 (en) | 2019-03-19 | 2021-09-16 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy for the treatment of cancer |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
WO2023150677A2 (en) * | 2022-02-03 | 2023-08-10 | Igm Biosciences, Inc. | Anti-cd38 binding molecules and uses thereof |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0605522B1 (en) * | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
ATE196606T1 (de) * | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US20030143233A1 (en) * | 1999-06-07 | 2003-07-31 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
ATE349438T1 (de) * | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
PL373594A1 (en) * | 2001-10-04 | 2005-09-05 | Immunex Corporation | Ul16 binding protein 4 |
EP1482972A4 (en) * | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES |
US6716821B2 (en) * | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
AU2002367318B2 (en) * | 2002-01-02 | 2007-07-12 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
BRPI0410260A (pt) * | 2003-05-14 | 2006-05-16 | Immunogen Inc | composição conjugada para medicamento |
-
2004
- 2004-07-21 BR BRPI0412879A patent/BRPI0412879A8/pt not_active Application Discontinuation
- 2004-07-21 PL PL04778714T patent/PL1660513T3/pl unknown
- 2004-07-21 US US10/895,135 patent/US20050123549A1/en not_active Abandoned
- 2004-07-21 DE DE602004031239T patent/DE602004031239D1/de active Active
- 2004-07-21 KR KR1020067001429A patent/KR101263950B1/ko not_active IP Right Cessation
- 2004-07-21 NZ NZ612796A patent/NZ612796A/en not_active IP Right Cessation
- 2004-07-21 EA EA200600275A patent/EA014640B1/ru not_active IP Right Cessation
- 2004-07-21 SI SI200431646T patent/SI1660513T1/sl unknown
- 2004-07-21 AU AU2004258955A patent/AU2004258955C1/en not_active Ceased
- 2004-07-21 NZ NZ598504A patent/NZ598504A/xx not_active IP Right Cessation
- 2004-07-21 DK DK04778714.8T patent/DK1660513T5/da active
- 2004-07-21 KR KR1020127024607A patent/KR20120113811A/ko active Search and Examination
- 2004-07-21 ES ES04778714T patent/ES2360403T3/es active Active
- 2004-07-21 JP JP2006521193A patent/JP2007503202A/ja active Pending
- 2004-07-21 CN CN201310020230.XA patent/CN103145844B/zh active Active
- 2004-07-21 PT PT04778714T patent/PT1660513E/pt unknown
- 2004-07-21 WO PCT/US2004/023340 patent/WO2005009369A2/en active Application Filing
- 2004-07-21 MX MXPA06000830A patent/MXPA06000830A/es active IP Right Grant
- 2004-07-21 EP EP04778714A patent/EP1660513B9/en active Active
- 2004-07-21 KR KR1020127013238A patent/KR20120059657A/ko not_active Application Discontinuation
- 2004-07-21 AT AT04778714T patent/ATE496944T1/de active
- 2004-07-21 KR KR1020147008527A patent/KR101565721B1/ko active IP Right Grant
- 2004-07-21 CN CN201310444419.1A patent/CN103554261B/zh active Active
- 2004-07-21 NZ NZ580855A patent/NZ580855A/en not_active IP Right Cessation
- 2004-07-21 KR KR1020157031117A patent/KR101672664B1/ko active IP Right Grant
- 2004-07-21 CN CN2004800243313A patent/CN1922199B/zh active Active
- 2004-07-21 CA CA2532430A patent/CA2532430C/en not_active Expired - Fee Related
-
2006
- 2006-01-05 IL IL172982A patent/IL172982A/en active IP Right Grant
- 2006-01-13 ZA ZA2006/00375A patent/ZA200600375B/en unknown
- 2006-01-19 EC EC2006006294A patent/ECSP066294A/es unknown
- 2006-01-20 MX MX2011000245A patent/MX336469B/es unknown
- 2006-01-20 CR CR8207A patent/CR8207A/es unknown
- 2006-02-20 NO NO20060812A patent/NO339324B1/no not_active IP Right Cessation
-
2007
- 2007-04-26 HK HK07104440.1A patent/HK1098160A1/xx not_active IP Right Cessation
- 2007-04-26 HK HK13113291.4A patent/HK1185891A1/zh not_active IP Right Cessation
-
2010
- 2010-11-25 JP JP2010262151A patent/JP5643619B2/ja not_active Expired - Fee Related
-
2011
- 2011-04-21 CY CY20111100408T patent/CY1111938T1/el unknown
- 2011-04-22 HR HR20110302T patent/HRP20110302T1/hr unknown
-
2014
- 2014-06-30 JP JP2014133794A patent/JP5997727B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-29 IL IL242336A patent/IL242336A/en active IP Right Grant
- 2015-12-04 JP JP2015237469A patent/JP6144749B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-24 JP JP2017033672A patent/JP2017123857A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412879A (pt) | conjugado citotóxico especìfico do antìgeno ca6 e métodos de seu uso | |
EA200800642A1 (ru) | Специфичный к антигену са6 цитотоксический конъюгат и способы его применения | |
DK1594542T3 (da) | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer | |
WO2008010101A8 (en) | Antagonist antibody against epha2 for the treatment of cancer | |
NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
RU2010148740A (ru) | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) | |
WO2006099141A3 (en) | Anti-mesothelin antibodies | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
ES2293973T3 (es) | Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos. | |
EP1476120A4 (en) | THERAPEUTIC METHODS USING ANTI-CD22 ANTIBODIES | |
MX2020011554A (es) | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19). | |
DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
NZ593171A (en) | Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent | |
MX2022005222A (es) | Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco. | |
CR9823A (es) | Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo | |
TH125460A (th) | แอนทาโกนิสต์แอนติบอดีสำหรับการรักษามะเร็ง | |
TH125460B (th) | แอนทาโกนิสต์แอนติบอดีสำหรับการรักษามะเร็ง | |
ATE469352T1 (de) | Specific monoclonal antibody against terbinafine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: IMMUNOGEN, INC. (US) Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110101858/RJ DE 30/09/2011. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 21/04 , C07K 16/00 , A61K 39/395 Ipc: C07K 16/30 (2006.01), A61K 39/395 (2006.01), C07K |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |